ProQR Therapeutics (PRQR) director reports five long-dated option grants

Rhea-AI Filing Summary

ProQR Therapeutics N.V. director Begona Carreno-Gomez has reported existing holdings of five share option awards over Ordinary Shares. These options carry exercise prices of $0.95, $1.98, $2.02, $2.65 and $3.41 per share, with underlying amounts of 3,565, 23,489, 25,192, 22,128 and 22,903 Ordinary Shares and expirations between October 31, 2032 and December 31, 2035. For each grant, 25% of the shares vest on specified dates from November 1, 2023 through January 1, 2027, with the remaining 75% vesting in 12 substantially equal quarterly installments, subject to her continuous service.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Carreno-Gomez Begona

Role Director

Type	Security	Shares	Price	Value
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--

Holdings After Transaction: Share Option (Right to Buy) — 3,565 shares (Direct)

Footnotes (1)

1. 25% of the shares subject to such option vest and become exercisable on November 1, 2023, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Carreno-Gomez Begona

(Last) (First) (Middle)

PROQR THERAPEUTICS N.V.

ZERNIKEDREEF 9

(Street)

LEIDEN 2333 CK

(City) (State) (Zip)

NETHERLANDS

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ProQR Therapeutics N.V. [ PRQR ]

3a. Foreign Trading Symbol
[N/A]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(1)	10/31/2032	Ordinary Shares	3,565	$0.95	D
Share Option (Right to Buy)	(2)	12/31/2032	Ordinary Shares	22,903	$3.41	D
Share Option (Right to Buy)	(3)	12/31/2033	Ordinary Shares	23,489	$1.98	D
Share Option (Right to Buy)	(4)	12/31/2034	Ordinary Shares	22,128	$2.65	D
Share Option (Right to Buy)	(5)	12/31/2035	Ordinary Shares	25,192	$2.02	D

Explanation of Responses:

1. 25% of the shares subject to such option vest and become exercisable on November 1, 2023, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

2. 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

3. 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

4. 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

5. 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Pieter Erik de Ridders, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does ProQR Therapeutics (PRQR) director Begona Carreno-Gomez report in this Form 3?

She reports existing holdings of five share option awards over ProQR Ordinary Shares. Each option gives a right to buy shares at set exercise prices and expirations, with multi-year vesting schedules tied to her continued service with the company.

What are the exercise prices of Begona Carreno-Gomez’s ProQR share options?

Her reported share options have exercise prices of $0.95, $1.98, $2.02, $2.65 and $3.41 per Ordinary Share. These fixed prices define what she must pay per share if she chooses to exercise each option grant in the future.

How many ProQR Ordinary Shares underlie the director’s reported share options?

The filing lists option grants over 3,565, 22,903, 23,489, 22,128 and 25,192 underlying Ordinary Shares. Each block corresponds to a separate option award, providing potential future equity exposure if the options vest and are exercised.

When do Begona Carreno-Gomez’s ProQR share options expire?

The options expire on dates ranging from October 31, 2032 to December 31, 2035. Each grant has its own expiration date, defining the last day on which she can exercise that particular option for ProQR Ordinary Shares.

How do the vesting schedules work for the ProQR director’s option grants?

For each grant, 25% of the shares vest on a specified initial date between November 2023 and January 2027. The remaining 75% then vest in 12 substantially equal quarterly installments, contingent on her continuous service to ProQR Therapeutics.

Is this ProQR filing showing new share purchases or sales by the director?

No purchases or sales are reported; it lists existing option holdings. The entries are classified as holdings of derivative securities, showing exercise prices, expirations and vesting terms rather than open-market buy or sell transactions in ProQR Ordinary Shares.